2 results
Approved WMOCompleted
Primary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48Secondary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg…
Approved WMORecruiting
The primary objective is to determine if repeated GON-injection result in effective control of cluster headache attacks for more months compared to placebo in chronic cluster headache. Secondary objectives are to determine:- If the effect of one GON…